The intravascular hemolysis of the AHTR produces the classic signs of hemoglobinemia and hemoglobinuria, which are pathognomonic of this condition (they may occur in extravascular HTR if very ...

The disease is currently treated with C5 inhibitors, but these fail to address extravascular hemolysis, a key issue in PNH management. Zaltenibart is an investigational MASP-3 inhibitor ...